Abstract
Osimertinib is a standard of care for advanced EGFR-mutated non-small cell lung cancer (EGFR+NSCLC), however acquired resistance inevitably develop in 1-2 year. No effective targeted therapy has been established for EGFR+NSCLC after osimertinib. The EGFR C797S (CS) mutation is one of the most common resistant mechanisms to osimertinib. Brigatinib is shown to overcome CS-mediated osimertinib resistance in combination with anti-EGFR antibody in preclinical models.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call